LOUISVILLE, Colo. --(BUSINESS WIRE)--Oct. 18, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday,

Analysis of 35,000 patients tested with Nodify Lung® Nodule Risk Assessment in a real-world setting to be presented at CHEST 2024 and launch of a new clinical study designed to expand data package LOUISVILLE, Colo. --(BUSINESS WIRE)--Oct. 7, 2024-- Biodesix, Inc.

LOUISVILLE, Colo. --(BUSINESS WIRE)--Sep. 5, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that members of the Biodesix management team will present at two upcoming investor conferences: Lake Street Capital Markets 8 th

Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million ; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from $65-68 million ; Q2 24 Net loss, including certain non-cash items, and Adjusted EBITDA improved by 19% and

LOUISVILLE, Colo. --(BUSINESS WIRE)--Aug. 6, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton , Chief Executive Officer of Biodesix , will present in a fireside chat and host in-person 1x1 investor meetings

LOUISVILLE, Colo. --(BUSINESS WIRE)--Jul. 24, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it will release financial results for the second quarter ended June 30, 2024 after the close of trading on Wednesday, August 7 .

Awarding Excellence in Company Culture LOUISVILLE, Colo. --(BUSINESS WIRE)--Jun. 18, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list . The ranking is a result of a comprehensive,

LOUISVILLE, Colo. --(BUSINESS WIRE)--May 28, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44 th Annual Growth

Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema LOUISVILLE, Colo. --(BUSINESS WIRE)--May 21, 2024-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented

First quarter 2024 Total Revenue of $14.8 million , a year-over-year increase of 64%, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume; First quarter 2024 gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth quarter of 2023; Raised $55